Q11201 (Q11201): Difference between revisions
Jump to navigation
Jump to search
(Removed claims) |
(Changed an Item) |
||||||||||||||
| Property / EU contribution | |||||||||||||||
5,769,000.0 Czech koruna
| |||||||||||||||
| Property / EU contribution: 5,769,000.0 Czech koruna / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / EU contribution | |||||||||||||||
230,760.0 Euro
| |||||||||||||||
| Property / EU contribution: 230,760.0 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / EU contribution: 230,760.0 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / EU contribution: 230,760.0 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
| Property / budget | |||||||||||||||
15,384,000.0 Czech koruna
| |||||||||||||||
| Property / budget: 15,384,000.0 Czech koruna / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / budget | |||||||||||||||
615,360.0 Euro
| |||||||||||||||
| Property / budget: 615,360.0 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / budget: 615,360.0 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / budget: 615,360.0 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
Revision as of 00:18, 12 February 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project in Czech Republic financed by DG Regio |
Statements
5,769,000.0 Czech koruna
0 references
15,384,000.0 Czech koruna
0 references
37.5 percent
0 references
12 May 2017
0 references
17 April 2020
0 references
VUAB Pharma a.s.
0 references
50°9'46.91"N, 14°23'2.26"E
0 references
25263
0 references
Předmětem projektu je vývoj postupu přípravy vysoce účinných proteolytik (KR-X) z antarktického krillu, které budou použity v různých oborech medicíny. Výstupem, kromě technologických postupů přípravy, budou dva prototypy proteolytika KR-X - pro léčbu chronických ran a pro trombolýzu cévních trombů. Díky mechanismu působení enzymu na nežádoucí fibrin a fragmenty se předpokládá u pacientů lepší snášenlivost a nižší bolestivost léčby oproti agresívnějším enzymatickým prostředkům. a. (Czech)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/16_083/0010108
0 references